SG11201807912SA - Vaccine against rsv - Google Patents
Vaccine against rsvInfo
- Publication number
- SG11201807912SA SG11201807912SA SG11201807912SA SG11201807912SA SG11201807912SA SG 11201807912S A SG11201807912S A SG 11201807912SA SG 11201807912S A SG11201807912S A SG 11201807912SA SG 11201807912S A SG11201807912S A SG 11201807912SA SG 11201807912S A SG11201807912S A SG 11201807912SA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- archimedesweg
- leiden
- rsv
- pct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18571—Demonstrated in vivo effect
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 11 M1111101110101011111 HO 11111 011101011101111101100 1111 DIM III International Bureau ... .... ..Yjd (10) International Publication Number ..... ...,/ (43) International Publication Date WO 2017/174564 Al 12 October 2017(12.10.2017) WIPO I PCT (51) International Patent Classification: A61K 39/12 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (21) International Application Number: PCT/EP2017/057957 MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (22) International Filing Date: 4 April 2017 (04.04.2017) RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: 16163807.7 5 April 2016 (05.04.2016) EP GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, (71) Applicant: JANSSEN VACCINES & PREVENTION B.V. [NL/NL]; Archimedesweg 4, 2333 CN Leiden (NL). DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (72) Inventors: LANGEDIJK, Johannes, Petrus, Maria; Archimedesweg 4-6, 2333 CN Leiden (NL). VERHA- GEN, Janneke, M; Archimedesweg 4-6, 2333 CN Leiden SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: (NL). — as to applicant's entitlement to apply for and be granted a — (74) Agents: MANTEN, Annemieke et al.; Archimedesweg 4- 6, 2333 CN Leiden (NL). patent (Rule 4.17(11)) — of inventorship (Rule 4.17(iv)) = (81) Designated States (unless otherwise indicated, for every Published: kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, — with international search report (Art. 21(3)) = = = = = = = = = = = = 1-1 7r ,tD 1 1 in IN ,—, IN IN 1-1 (54) Title: VACCINE AGAINST RSV 0 ei (57) : The present invention relates to novel nucleic acid molecules encoding a pre- fusion RSV F protein or immunologic - en. ) ally active part thereof, wherein the pre-fusion RSV F protein comprises the amino acid sequence of SEQ ID NO: 1 or 2. The inven - '' ,... °. tion further relates to the use of the nucleic acid molecules, or vectors comprising said nucleic acid molecules, as a vaccine against respiratory syncytial virus (RSV).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16163807 | 2016-04-05 | ||
PCT/EP2017/057957 WO2017174564A1 (en) | 2016-04-05 | 2017-04-04 | Vaccine against rsv |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201807912SA true SG11201807912SA (en) | 2018-10-30 |
Family
ID=55661317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201807912SA SG11201807912SA (en) | 2016-04-05 | 2017-04-04 | Vaccine against rsv |
Country Status (18)
Country | Link |
---|---|
US (3) | US10729757B2 (en) |
EP (1) | EP3439694A1 (en) |
JP (2) | JP7233928B2 (en) |
KR (3) | KR102401247B1 (en) |
CN (1) | CN109069612A (en) |
AU (1) | AU2017248018A1 (en) |
BR (1) | BR112018070323A2 (en) |
CA (1) | CA3018139A1 (en) |
CL (1) | CL2018002825A1 (en) |
EA (1) | EA201892250A1 (en) |
IL (1) | IL262109B2 (en) |
MA (1) | MA43762A (en) |
MX (1) | MX2018012095A (en) |
MY (1) | MY193584A (en) |
PE (1) | PE20190433A1 (en) |
PH (1) | PH12018501912A1 (en) |
SG (1) | SG11201807912SA (en) |
WO (1) | WO2017174564A1 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105188745B (en) * | 2013-04-25 | 2019-10-18 | 扬森疫苗与预防公司 | RSV F polypeptide before stabilized soluble fusion |
US10457708B2 (en) | 2015-07-07 | 2019-10-29 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
PL3319633T3 (en) * | 2015-07-07 | 2021-04-19 | Janssen Vaccines & Prevention B.V. | Vaccine against rsv |
EP4011451A1 (en) | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Metapneumovirus mrna vaccines |
WO2017174564A1 (en) * | 2016-04-05 | 2017-10-12 | Janssen Vaccines & Prevention B.V. | Vaccine against rsv |
AU2017248021B2 (en) * | 2016-04-05 | 2021-08-12 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F proteins |
JP2019523644A (en) | 2016-05-30 | 2019-08-29 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | Stabilized pre-fusion RSV F protein |
MA47787A (en) | 2017-03-15 | 2020-01-22 | Modernatx Inc | RESPIRATORY SYNCYTIAL VIRUS VACCINE |
CA3061278A1 (en) * | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
WO2019053109A1 (en) * | 2017-09-15 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | Method for the safe induction of immunity against rsv |
MA54676A (en) * | 2018-01-29 | 2021-11-17 | Modernatx Inc | RSV RNA VACCINES |
WO2020229577A1 (en) | 2019-05-15 | 2020-11-19 | Janssen Vaccines & Prevention B.V. | Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine |
AU2020275910A1 (en) * | 2019-05-15 | 2021-11-04 | Janssen Vaccines & Prevention B.V. | Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine |
IL299515A (en) | 2020-06-29 | 2023-02-01 | Janssen Vaccines & Prevention Bv | Vaccine combination against respiratory syncytial virus infection |
CN112220921B (en) * | 2020-08-25 | 2022-08-16 | 北京交通大学 | Combined vaccine for respiratory syncytial virus infection |
WO2022175479A1 (en) | 2021-02-19 | 2022-08-25 | Janssen Vaccines & Prevention B.V. | Vaccine combinations against respiratory syncytial virus strain a and b infections |
CN114277039A (en) * | 2021-10-25 | 2022-04-05 | 浙江君怡生物科技有限公司 | Respiratory syncytial virus mRNA vaccine and preparation method and application thereof |
WO2023198815A1 (en) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Sequential administration of adenoviruses |
WO2024041772A1 (en) * | 2022-08-22 | 2024-02-29 | Glaxosmithkline Biologicals Sa | Rsv-f proteins |
WO2024069420A2 (en) | 2022-09-29 | 2024-04-04 | Pfizer Inc. | Immunogenic compositions comprising an rsv f protein trimer |
WO2024089634A1 (en) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Immunogenic compositions against influenza and rsv |
WO2024089633A1 (en) | 2022-10-27 | 2024-05-02 | Pfizer Inc. | Rna molecules encoding rsv-f and vaccines containing them |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
US4372945A (en) | 1979-11-13 | 1983-02-08 | Likhite Vilas V | Antigen compounds |
IL61904A (en) | 1981-01-13 | 1985-07-31 | Yeda Res & Dev | Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same |
EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
NZ230747A (en) | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
WO1990014837A1 (en) | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
FR2705686B1 (en) | 1993-05-28 | 1995-08-18 | Transgene Sa | New defective adenoviruses and corresponding complementation lines. |
US5851806A (en) | 1994-06-10 | 1998-12-22 | Genvec, Inc. | Complementary adenoviral systems and cell lines |
ATE336587T1 (en) | 1994-06-10 | 2006-09-15 | Genvec Inc | ADENOVIRUS VECTOR SYSTEMS AND CELL LINES |
US5846782A (en) | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US5965541A (en) | 1995-11-28 | 1999-10-12 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US5559099A (en) | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
AUPM873294A0 (en) | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
SI0833934T2 (en) | 1995-06-15 | 2013-04-30 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
US5837511A (en) | 1995-10-02 | 1998-11-17 | Cornell Research Foundation, Inc. | Non-group C adenoviral vectors |
US5891690A (en) | 1996-04-26 | 1999-04-06 | Massie; Bernard | Adenovirus E1-complementing cell lines |
US6485958B2 (en) | 1996-07-01 | 2002-11-26 | Gencell Sa | Method for producing recombinant adenovirus |
FR2751343B1 (en) | 1996-07-16 | 1998-12-18 | Transgene Sa | PROCESS FOR THE PRESERVATION OF INFECTIOUS RECOMBINANT VIRUSES, AQUEOUS VIRAL SUSPENSION, AND USE AS A MEDICAMENT |
US6083716A (en) | 1996-09-06 | 2000-07-04 | The Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
EP0968284B1 (en) | 1996-11-20 | 2006-12-13 | Introgen Therapeutics, Inc. | An improved method for the production and purification of adenoviral vectors |
US7732129B1 (en) | 1998-12-01 | 2010-06-08 | Crucell Holland B.V. | Method for the production and purification of adenoviral vectors |
US6261823B1 (en) | 1996-12-13 | 2001-07-17 | Schering Corporation | Methods for purifying viruses |
EP0973866A4 (en) | 1997-03-04 | 2000-04-19 | Baxter Int | Adenovirus e1-complementing cell lines |
US6020191A (en) | 1997-04-14 | 2000-02-01 | Genzyme Corporation | Adenoviral vectors capable of facilitating increased persistence of transgene expression |
US6210683B1 (en) | 1997-09-05 | 2001-04-03 | Merck & Co., Inc. | Stabilizers containing recombinant human serum albumin for live virus vaccines |
ID28298A (en) | 1998-02-17 | 2001-05-10 | Schering Corp | COMPOSITION THAT CONTAIN VIRUSES AND METHODS TO ADAPT VIRUS PREPARATES |
US5981225A (en) | 1998-04-16 | 1999-11-09 | Baylor College Of Medicine | Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same |
US6113913A (en) | 1998-06-26 | 2000-09-05 | Genvec, Inc. | Recombinant adenovirus |
ATE421337T1 (en) | 1998-11-16 | 2009-02-15 | Introgen Therapeutics Inc | ADENOVIRUS FORMULATIONS FOR GENE THERAPY |
US6225289B1 (en) | 1998-12-10 | 2001-05-01 | Genvec, Inc. | Methods and compositions for preserving adenoviral vectors |
ATE519854T1 (en) | 1999-05-17 | 2011-08-15 | Crucell Holland Bv | RECOMBINANT ADENOVIRUS BASED ON SEROTYPE 48 (AD48). |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
DE19955558C2 (en) | 1999-11-18 | 2003-03-20 | Stefan Kochanek | Permanent amniocyte cell line, its production and use for the production of gene transfer vectors |
WO2001066137A1 (en) | 2000-03-07 | 2001-09-13 | Merck & Co., Inc. | Adenovirus formulations |
JP2004519204A (en) | 2000-05-08 | 2004-07-02 | ダビスコ フーズ インターナショナル インコーポレーテッド | Enzymatic treatment of whey protein for the production of anti-hypertensive peptides, resulting product and treatment of hypertension in mammals |
AUPR878401A0 (en) | 2001-11-09 | 2001-12-06 | Biota Holdings Ltd | Methods for identifying or screening anti-viral agents |
JP2005517394A (en) | 2001-12-12 | 2005-06-16 | エフ エイチ フォールディング アンド カンパニー リミテッド | Composition for virus preservation |
CA2469721A1 (en) | 2002-01-18 | 2003-07-31 | Schering Aktiengesellschaft | Stabilized formulations of adenovirus |
US20030180936A1 (en) | 2002-03-15 | 2003-09-25 | Memarzadeh Bahram Eric | Method for the purification, production and formulation of oncolytic adenoviruses |
CA2477954C (en) | 2002-04-25 | 2012-07-10 | Crucell Holland B.V. | Means and methods for the production of adenovirus vectors |
CA2478508C (en) | 2002-04-25 | 2013-07-02 | Crucell Holland B.V. | Stable adenoviral vectors and methods for propagation thereof |
AU2003229060A1 (en) | 2002-05-14 | 2003-12-02 | Merck And Co., Inc. | Methods of adenovirus purification |
SE0202110D0 (en) | 2002-07-05 | 2002-07-05 | Isconova Ab | Iscom preparation and use thereof |
US20040106184A1 (en) | 2002-08-28 | 2004-06-03 | Introgen Therapeutics Inc. | Chromatographic methods for adenovirus purification |
SE0301998D0 (en) | 2003-07-07 | 2003-07-07 | Isconova Ab | Quil A fraction with low toxicity and use thereof |
CA2553541C (en) | 2004-01-23 | 2015-04-21 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Chimpanzee adenovirus vaccine carriers |
DK1780269T3 (en) | 2004-02-23 | 2009-10-12 | Crucell Holland Bv | Virus Purification Methods |
DE602006003420D1 (en) | 2005-04-11 | 2008-12-11 | Crucell Holland Bv | VIRUS CLEANING WITH ULTRA FILTRATION |
WO2007104792A2 (en) | 2006-03-16 | 2007-09-20 | Crucell Holland B.V. | Recombinant adenoviruses based on serotype 26 and 48, and use thereof |
EP1998804B1 (en) | 2006-03-27 | 2014-04-16 | Crucell Holland B.V. | Compositions comprising a recombinant adenovirus and an adjuvant |
WO2008133663A2 (en) * | 2006-11-30 | 2008-11-06 | Government Of The United States Of America, As Represented By The Secretary, | Codon modified immunogenic compositions and methods of use |
US7901388B2 (en) | 2007-07-13 | 2011-03-08 | Bacoustics, Llc | Method of treating wounds by creating a therapeutic solution with ultrasonic waves |
EP3508505A1 (en) | 2007-12-24 | 2019-07-10 | ID Biomedical Corporation of Quebec | Recombinant rsv antigens |
WO2009106580A1 (en) | 2008-02-29 | 2009-09-03 | Tibotec Pharmaceuticals | Method for identifying inhibitors against viruses that use a class i fusion protein |
KR101504392B1 (en) | 2008-11-03 | 2015-03-19 | 크루셀 홀란드 비.브이. | Method for the production of adenoviral vectors |
HUE051666T2 (en) * | 2008-12-09 | 2021-03-29 | Novavax Inc | Modified rsv f proteins and methods of their use |
JP5882741B2 (en) | 2009-02-02 | 2016-03-09 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Nucleic acid and amino acid sequences of simian adenovirus, vectors containing the same, and uses thereof |
PL2445526T3 (en) | 2009-06-24 | 2017-08-31 | Glaxosmithkline Biologicals S.A. | Recombinant rsv antigens |
SG176807A1 (en) | 2009-06-24 | 2012-01-30 | Id Biomedical Corp Quebec | Vaccine |
WO2011008974A2 (en) | 2009-07-15 | 2011-01-20 | Novartis Ag | Rsv f protein compositions and methods for making same |
EP2464664B1 (en) | 2009-08-13 | 2015-09-23 | Crucell Holland B.V. | Antibodies against human respiratory syncytial virus (rsv) and methods of use |
EP2488635B1 (en) | 2009-10-15 | 2013-11-20 | Crucell Holland B.V. | Process for adenovirus purification from high cell density cultures |
CN102791852B (en) | 2009-10-15 | 2014-05-07 | 克鲁塞尔荷兰公司 | Method for the purification of adenovirus particles |
US20120315270A1 (en) | 2009-10-21 | 2012-12-13 | The United States Of America, As Represented By The | Rsv immunogens, antibodies and compositions thereof |
AU2011214262B2 (en) | 2010-02-15 | 2015-05-21 | Crucell Holland B.V. | Method for the production of Ad26 adenoviral vectors |
EP2591000B1 (en) | 2010-07-09 | 2017-05-17 | Janssen Vaccines & Prevention B.V. | Anti-human respiratory syncytial virus (rsv) antibodies and methods of use |
DK3275892T3 (en) | 2011-05-13 | 2020-04-06 | Glaxosmithkline Biologicals Sa | PRÆFUSIONS-RSV F ANTIGENS |
DK2825640T3 (en) | 2012-03-12 | 2016-08-01 | Crucell Holland Bv | BATCHES OF RECOMBINANT ADENOVIRUS WITH CHANGED TERMINAL END |
US8932607B2 (en) | 2012-03-12 | 2015-01-13 | Crucell Holland B.V. | Batches of recombinant adenovirus with altered terminal ends |
AP2014007993A0 (en) | 2012-03-22 | 2014-10-31 | Crucell Holland Bv | Vaccine against RSV |
WO2014005643A1 (en) | 2012-07-05 | 2014-01-09 | Okairos Ag | Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides |
JP6210998B2 (en) * | 2012-11-15 | 2017-10-11 | 一般財団法人化学及血清療法研究所 | Infectious disease prevention method by combined use of vector vaccine and live vaccine |
US9738689B2 (en) | 2013-03-13 | 2017-08-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion RSV F proteins and their use |
WO2014160463A1 (en) | 2013-03-13 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Prefusion rsv f proteins and their use |
CN105164155B (en) | 2013-04-15 | 2020-01-03 | 扬森疫苗与预防公司 | Human antibodies that bind to RSV G protein |
EP3567051A1 (en) | 2013-04-15 | 2019-11-13 | Janssen Vaccines & Prevention B.V. | Human antibodies binding to rsv g protein |
CN105188745B (en) | 2013-04-25 | 2019-10-18 | 扬森疫苗与预防公司 | RSV F polypeptide before stabilized soluble fusion |
EP3010931B1 (en) | 2013-06-17 | 2018-06-13 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion rsv f polypeptides |
WO2015013551A1 (en) | 2013-07-25 | 2015-01-29 | Marshall Christopher Patrick | Conformationally stabilized rsv pre-fusion f proteins |
US9974737B2 (en) | 2013-09-19 | 2018-05-22 | Janssen Vaccines & Prevention B.V. | Adenovirus formulations |
EP3888676A1 (en) | 2014-06-13 | 2021-10-06 | GlaxoSmithKline Biologicals S.A. | Immunogenic combinations |
US10457708B2 (en) | 2015-07-07 | 2019-10-29 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F polypeptides |
PL3319633T3 (en) | 2015-07-07 | 2021-04-19 | Janssen Vaccines & Prevention B.V. | Vaccine against rsv |
AU2017248021B2 (en) | 2016-04-05 | 2021-08-12 | Janssen Vaccines & Prevention B.V. | Stabilized soluble pre-fusion RSV F proteins |
WO2017174564A1 (en) | 2016-04-05 | 2017-10-12 | Janssen Vaccines & Prevention B.V. | Vaccine against rsv |
JP2019523644A (en) | 2016-05-30 | 2019-08-29 | ヤンセン ファッシンズ アンド プリベンション ベーフェーJanssen Vaccines & Prevention B.V. | Stabilized pre-fusion RSV F protein |
CA3061278A1 (en) | 2017-05-17 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against rsv infection |
WO2019053109A1 (en) | 2017-09-15 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | Method for the safe induction of immunity against rsv |
CR20210306A (en) | 2018-11-13 | 2021-07-22 | Janssen Vaccines & Prevention Bv | Stabilized pre-fusion rsv f proteins |
AU2020263900A1 (en) | 2019-04-25 | 2021-10-14 | Janssen Vaccines & Prevention B.V. | Recombinant influenza antigens |
AU2020275910A1 (en) | 2019-05-15 | 2021-11-04 | Janssen Vaccines & Prevention B.V. | Prophylactic treatment of respiratory syncytial virus infection with an adenovirus based vaccine |
CA3177062A1 (en) | 2020-04-02 | 2021-10-07 | Janssen Vaccines & Prevention B.V. | Stabilized vaccine compositions |
IL299515A (en) | 2020-06-29 | 2023-02-01 | Janssen Vaccines & Prevention Bv | Vaccine combination against respiratory syncytial virus infection |
-
2017
- 2017-04-04 WO PCT/EP2017/057957 patent/WO2017174564A1/en active Application Filing
- 2017-04-04 KR KR1020187031414A patent/KR102401247B1/en active IP Right Grant
- 2017-04-04 IL IL262109A patent/IL262109B2/en unknown
- 2017-04-04 JP JP2018551163A patent/JP7233928B2/en active Active
- 2017-04-04 MY MYPI2018703646A patent/MY193584A/en unknown
- 2017-04-04 EP EP17715691.6A patent/EP3439694A1/en active Pending
- 2017-04-04 BR BR112018070323A patent/BR112018070323A2/en unknown
- 2017-04-04 MA MA043762A patent/MA43762A/en unknown
- 2017-04-04 EA EA201892250A patent/EA201892250A1/en unknown
- 2017-04-04 KR KR1020227002657A patent/KR102491447B1/en active IP Right Grant
- 2017-04-04 CA CA3018139A patent/CA3018139A1/en active Pending
- 2017-04-04 MX MX2018012095A patent/MX2018012095A/en unknown
- 2017-04-04 KR KR1020227016835A patent/KR102500970B1/en active IP Right Grant
- 2017-04-04 PE PE2018001916A patent/PE20190433A1/en unknown
- 2017-04-04 CN CN201780021794.1A patent/CN109069612A/en active Pending
- 2017-04-04 AU AU2017248018A patent/AU2017248018A1/en active Pending
- 2017-04-04 SG SG11201807912SA patent/SG11201807912SA/en unknown
- 2017-04-04 US US16/091,257 patent/US10729757B2/en active Active
-
2018
- 2018-09-07 PH PH12018501912A patent/PH12018501912A1/en unknown
- 2018-10-04 CL CL2018002825A patent/CL2018002825A1/en unknown
-
2020
- 2020-06-24 US US16/946,485 patent/US11338031B2/en active Active
-
2022
- 2022-05-20 US US17/664,290 patent/US11801297B2/en active Active
- 2022-11-24 JP JP2022187453A patent/JP2023029889A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MY193584A (en) | 2022-10-19 |
KR20220075436A (en) | 2022-06-08 |
US11338031B2 (en) | 2022-05-24 |
US20220288186A1 (en) | 2022-09-15 |
CN109069612A (en) | 2018-12-21 |
MX2018012095A (en) | 2019-01-10 |
US10729757B2 (en) | 2020-08-04 |
KR102500970B1 (en) | 2023-02-17 |
KR20220018618A (en) | 2022-02-15 |
EP3439694A1 (en) | 2019-02-13 |
PH12018501912A1 (en) | 2019-06-17 |
KR20180132761A (en) | 2018-12-12 |
JP7233928B2 (en) | 2023-03-07 |
US20190125854A1 (en) | 2019-05-02 |
US20200360506A1 (en) | 2020-11-19 |
JP2019510497A (en) | 2019-04-18 |
JP2023029889A (en) | 2023-03-07 |
KR102491447B1 (en) | 2023-01-20 |
IL262109B2 (en) | 2023-04-01 |
KR102401247B1 (en) | 2022-05-25 |
PE20190433A1 (en) | 2019-03-21 |
US11801297B2 (en) | 2023-10-31 |
BR112018070323A2 (en) | 2019-01-29 |
EA201892250A1 (en) | 2019-03-29 |
WO2017174564A1 (en) | 2017-10-12 |
CA3018139A1 (en) | 2017-10-12 |
AU2017248018A1 (en) | 2018-09-27 |
IL262109A (en) | 2018-11-29 |
MA43762A (en) | 2021-04-21 |
IL262109B (en) | 2022-12-01 |
CL2018002825A1 (en) | 2018-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201807912SA (en) | Vaccine against rsv | |
SG11201804411TA (en) | Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201807913XA (en) | Stabilized soluble pre-fusion rsv f proteins | |
SG11201901206SA (en) | Trimer stabilizing hiv envelope protein mutations | |
SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
SG11201804373VA (en) | Compositions and methods for immunooncology | |
SG11201810078PA (en) | Stabilized pre-fusion rsv f proteins | |
SG11201903287PA (en) | Anti-respiratory syncytial virus antibodies, and methods of their generation and use | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201811363YA (en) | Anti-zika virus antibodies and methods of use | |
SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
SG11201811442UA (en) | Formulation of a peptide vaccine | |
SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
SG11201909011PA (en) | Niraparib compositions | |
SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
SG11201901351UA (en) | A patient interface, system and method | |
SG11201902531QA (en) | Liquid pharmaceutical composition | |
SG11201810429UA (en) | Anti-cd19 antibody formulations | |
SG11201907927SA (en) | Binding molecules that specifically bind to tau | |
SG11201404836QA (en) | Long-acting coagulation factors and methods of producing same |